Abstract. Gliomas are a primary types of intracranial malignancies and are characterized by a poor prognosis due to aggressive recurrence profiles. Temozolomide (TMZ) is an auxiliary alkylating agent that is extensively used in conjunction with surgical resection and forms the mainstay of clinical treatment strategies for gliomas. However, the frequent occurrence of TMZ resistance in clinical practice limits its therapeutic efficacy. Accumulating evidence has demonstrated that long non-coding RNAs (lncRNAs) can play key and varied roles in glioma progression. lncRNAs have been reported to inhibit glioma progression by targeting various signaling pathways. In addition, the differential expression of lncRNAs has also been found to mediate the resistance of glioma to several chemotherapeutic agents, particularly to TMZ. The present review article therefore summarizes the findings of previous studies in an aim to report the significance and function of lncRNAs in regulating the chemoresistance of gliomas. The present review may provide further insight into the clinical treatment of gliomas.

Contents

1. Introduction
2. Prominent role of lncRNAs in glioma
3. Oncogenic IncRNAs promote TMZ resistance in gliomas
4. Tumor suppressive IncRNAs influence the sensitivity of gliomas to TMZ
5. Conclusions and future perspectives

1. Introduction

The World Health Organization (WHO) currently classifies gliomas into four grades, where a new classification was proposed in 2016 (1). These grades of interest are as follows: i) Diffuse low-grade gliomas (WHO I and II), which include diffuse astrocytoma and oligodendroglioma; ii) diffuse high-grade gliomas (WHO III), which include anaplastic astrocytoma with various mutated genes; and iii) glioblastoma (GBM; WHO IV), which is the most lethal variety of glioma (2). Glioblastoma multiforme (GBM) is a common type of brain malignancy that remains largely incurable. Despite the development of multi-modal therapeutic interventions, such as radiotherapy combined with temozolomide (TMZ) (3) and electrofield therapy combined with TMZ (4), the median survival rate of patients with GBM remains at ≤15 months (5).

TMZ is an orally administered alkylating antitumor drug that can cross the blood-brain barrier with a bioavailability reaching ~100%. It can be used to effectively treat newly diagnosed and relapsed GBM to prolong the survival rate of patients (6,7). Thus, TMZ is the main adjuvant therapeutic agent used in the treatment of glioma in clinical practice (8). However, the development of resistance to TMZ in glioma impairs its therapeutic efficacy, resulting in recurrence (9). A previous study evaluated the responses of 1,035 GBM tumors to therapies using multiple assaying technologies and discovered that gene mutations are largely responsible for resistance to treatment. The mechanisms of action of TMZ involve the alkylation of the O6 site of guanine (O6MeG), resulting in a base mismatch following subsequent DNA replication, causing DNA damage (10). TMZ resistance has become one of the largest obstacles in prolonging the survival of patients with glioma. Several mechanisms have been proposed to underlie the resistance to TMZ. The most common mode lies in the DNA repair system, including the O6MeG DNA
In conclusion, IncRNAs are promising therapeutic targets for the treatment of human diseases, particularly glioma. Therefore, the present review article first summarizes research findings from the past 5 years regarding the signaling pathways underlying the resistance of glioma to TMZ, with a focus on oncogenic or tumor suppressive IncRNAs. Moreover, the association between IncRNAs and combination therapy with TMZ and immunosuppressive therapy for glioma is discussed, in an aim to provide further insight into the clinical treatment of glioma.

2. Prominent role of IncRNAs in glioma

In 2012, Zhang et al (33) first associated IncRNA expression with the grade of malignancy in human glioma. Furthermore, IncRNAs have been reported to be associated with the occurrence and progression of various malignancies such as colorectal cancer, gallbladder cancer, ovarian cancer in addition to modulating chemoresistance in glioma (34-38). The expression of a number of IncRNAs has been found to be upregulated in glioma and these IncRNAs have been proposed to function as oncogenes, whilst the expression levels of other IncRNAs have been found to be downregulated in glioma and those IncRNAs have been proposed to function as tumor suppressor genes. From an epigenetic perspective, IncRNAs play a key role in glioma. IncRNA maternally expressed 3 (MEG3) expression was previously reported to be decreased in glioma tissues due to its hypermethylation. Upstream, DNA methyltransferase 1 (DNMT1) was found to be the mediator of MEG3 promoter methylation, which suppressed the transcription of MEG3. In addition, DNMT1 promoted the proliferation and clonogenicity of glioma cells, whilst reducing apoptosis. The inhibition of DNMT1 was demonstrated to activate the p53 signaling pathway in glioma cells. Therefore, MEG3 hypermethylation by DNMT1 was concluded to decrease MEG3 expression, which may represent a molecular mechanism of glioma progression (39). In GBM cells with acquired TMZ resistance, a previous study found that 1,383 IncRNAs were significantly upregulated, whereas 1,309 IncRNAs were significantly downregulated compared with normal GBM cell lines using a human IncRNA microarray; this suggests that IncRNAs are closely associated with TMZ resistance (40). IncRNA long intergenic non-protein coding RNA (LINC)00473, the expression of which was found to be significantly increased in glioma, was found to be associated with a poor prognosis of patients with glioma by functioning as an oncogenic IncRNA (41). In addition, LINC00473 knockdown was revealed to inhibit glioma progression both in vivo and in vitro. The underlying mechanism was proposed to be the inhibition of miR-195-5p by LINC00473 by competing for binding to the same sites on the corresponding mRNA. Downstream, Yes-associated protein 1 (YAP1) and TEA domain family member 1 (TEAD1) were found to be downstream targets of miR-195-5p, where both shared a negative correlation. Taken together, LINC00473 downregulation inhibited glioma growth by serving as a competing endogenous RNA (ceRNA) to block miR-195-5p function, thereby promoting YAP1 and TEAD1 expression (41). In another study, IncRNA small nucleolar RNA
host gene (SNHG12) was found to be highly expressed in glioma, where functional analyses revealed that SNHG12 knockdown inhibited the proliferation and promoted the apoptosis of glioma cells (42). Downstream, SNHG12 was demonstrated to interact with Hu antigen R (HuR), an ubiquitous multi-faceted RNA-binding protein, to become stabilized (42). Furthermore, the IncRNA HOX antisense intergenic RNA (HOTAIR) was found to function as an oncogene that is highly expressed in glioma stem cells (GSCs). Functional assays revealed that downregulating HOTAIR expression suppressed GSC development by targeting the programmed cell death 4 protein (43). IncRNA H19 has also been reported to be highly expressed and negatively associated with miR-138 expression in glioma cell lines, according to reverse transcription-quantitative PCR (RT-qPCR) data (44). H19 knockdown was found to suppress angiogenesis in glioma, specifically by functioning as a ceRNA of miR-138 to inhibit its function, thereby promoting the expression of hypoxia-inducible transcription factors and VEGFs (44). In addition, H19 downregulation was also found to inhibit the angiogenesis of glioma by directly binding to miR-29a, which in turn inhibited vasohibin 2 expression, an angiogenic factor in glioma (45). A previous study demonstrated that the expression of the IncRNA colorectal neoplasia differentially expressed (CRNDE) was upregulated in glioma tissues and cells; subsequent functional analyses demonstrated that CRNDE promoted glioma cell proliferation in a mTOR signaling-dependent manner in glioma (46). Downstream, miR-384 expression was also revealed to be downregulated in glioma and inhibited by CRNDE, which increased the expression of piwi-like RNA-mediated gene silencing 4 protein (47). In addition, the IncRNA-MUF, which was induced by TGF-β, was reported to be another oncogene in GBM. The knockdown of IncRNA-MUF expression suppressed tumor growth and promoted apoptosis induced by TMZ by targeting miR-34a (48).

However, IncRNA taurine upregulated 1 (TUG1) was considered to be a suppressor of glioma cell proliferation by promoting apoptosis. The overexpression of TUG1 was found to increase the expression of caspases-3 and -9, whilst decreasing the expression of Bcl-1, suggesting that the suppressive effects of TUG1 were due to the inhibition of the pathways associated with cell apoptosis (49).

Gliomas have also been reported to regulate the expression of certain IncRNAs. Glioma cells retain the ability to secrete exosomes containing miRNAs, miRNAs, IncRNAs, and angiogenic proteins into the surrounding microenvironment to regulate the function of target cells, by targeting downstream signaling pathways (50,51). Using electron microscopy and western blot analysis, exosomes secreted by glioma cells were previously found to transport IncRNA-activated by TGF-β (ATB) into astrocytes to activate them. Subsequently, IncRNA-ATB in glioma cell-derived exosomes were demonstrated to promote the proliferation of glioma cells by inhibiting miR-204-3p (52). Angiogenesis also plays a key role in glioma growth. It was reported that glioma-derived exosomes enriched in IncRNA-POU class 3 homeobox 3 promoted angiogenesis in glioma (53). Therefore, these aforementioned findings suggest that gliomas can export IncRNAs by secreting exosomes.

3. Oncogenic IncRNAs promote TMZ resistance in gliomas

Oncogenic IncRNAs (Table I) were previously found to be overexpressed or upregulated in gliomas, and this can promote TMZ resistance by targeting a multitude of signaling pathways.

c-Met pathway. c-Met is a receptor tyrosine kinase, the expression of which has been found to be upregulated in TMZ-resistant GBM (54). MGMT is an enzyme that removes the methyl group at O6MeG, thereby affecting the activity of TMZ (11). Wu et al (55) reported that IncRNA-TMZ-associated IncRNA (TALC), a novel IncRNA associated with GBM recurrence, upregulated the expression of MGMT and promoted TMZ resistance by activating c-Met signaling.

TGF-β1/Smad signaling pathway. TGF-β1 is a cytokine that plays a crucial role in promoting tumor growth (56). Smad proteins are phosphorylated by TGF-β1 receptors, which relays the TGF-β1 signal into the nucleus (57,58). TGF-β1 has been reported to be a novel player in mediating resistance against both targeted and conventional therapeutic agents (59). The mechanism underlying this process appears to be associated with epithelial-mesenchymal transition (EMT) and the activity of cancer stem cells (60). However, the effects of TGF-β1 signaling on TMZ resistance in glioma remain to be a subject of further exploration.

The knockdown of K-homology splicing regulatory protein (KSRP) expression has been demonstrated to inhibit the expression of miR-198 (61). In addition, miR-198 may enhance sensitivity to TMZ by inhibiting the expression of MGMT, which is abrogated by TGF-β1 through the suppression of KSRP expression in GBM cells. TGF-β1 may also upregulate the expression of IncRNAs H19 and HOXD cluster antisense RNA 2 by activating Smad, which promotes GBM resistance to TMZ by activating MGMT and inhibiting miR-198. However, KSRP knockdown was shown to abolish the effects of TGF-β1 and IncRNA H19 on miR-198 and MGMT. In the clinic, TMZ tended to be more effective in patients with lower expression levels of TGF-β1 or IncRNA H19. Collectively, these observations suggest that TGF-β1 can confer resistance to TMZ by regulating the processing of IncRNAs and increasing the expression of MGMT (61).

A literature search revealed various IncRNAs affecting TMZ resistance in glioma, as well as their functions and targets (62-82). This list of IncRNAs is presented in Table I.

Wnt/β-catenin signaling pathway. Using transcriptome sequencing, a previous study found that the Wnt/β-catenin pathway was significantly activated in TMZ-treated glioma cells in a P13K/Akt pathway-dependent manner. Mechanistically, Akt activation promoted β-catenin translocation into the nucleus, resulting in the transcriptional activation of Wnt/β-catenin signaling to suppress apoptosis whilst promoting TMZ resistance (83). Sex-determining region Y-box9 pro-tein (SOX9) has been found to be overexpressed in GBM, where it can stimulate GBM growth by activating Wnt/β-catenin signaling (84). In another study, Li et al (71) explored the effects of LINCO00174 on glioma cells. They found that LINCO00174 expression was increased in glioma tissues, and that LINCO00174 knockdown significantly inhibited the
proliferation of TMZ-resistant glioma cells. Mechanistically, the knockdown of LINC00174 expression suppressed the growth of TMZ-resistant glioma by sponging miR-138-5p, which negatively targets SOX9. Therefore, LINC00174 was proposed to activate Wnt/β-catenin signaling by targeting the miR-138-5p/SOX9 axis. Furthermore, in vivo experiments also revealed consistent findings (71).

It has been previously demonstrated that the expression level of IncRNA H19 is significantly increased in patients with glioma resistant to TMZ (73). An in vitro TMZ drug-resistant cell model was established and the model was verified using RT-qPCR. Silencing H19 expression enhanced the sensitivity of TMZ-resistant glioma cells to TMZ by downregulating the expression of a number of genes, including multidrug resistance mutation, multidrug resistance-associated protein and ATP binding cassette subfamily G member 2. Therefore, H19 was proposed to be a novel therapeutic target for TMZ-resistant gliomas (73).

In addition, other studies have previously investigated the specific mechanisms involved in IncRNA H19-mediated regulation. H19 knockdown was found to inhibit EMT by promoting the expression of the epithelial marker, E-cadherin, whilst inhibiting that of the mesenchymal markers, vimentin and zinc finger E-box binding homeobox (ZEB)1. Furthermore, H19 downregulation was found to decrease the expression of β-catenin and its downstream targets, c-Myc and surviving, in TMZ-treated glioma cells. However, H19 reversed the resistance of glioma cells to TMZ by repressing EMT and targeting the Wnt/β-catenin pathway (72). A recent study also reported that IncRNA PSMG3-AS1 was significantly upregulated in GBM. PSMG3-AS1 was observed to promote TMZ resistance in glioma cells by binding to c-Myc in the nucleus (74).

The silencing of IncRNA miR-155 host gene (MIR155HG) expression was previously reported to promote glioma sensitivity to TMZ through the Wnt/β-catenin pathway by
inhibiting poly-pyrimidine tract-binding protein 1 expression (64). Furthermore, the knockdown of LINC00511 expression enhanced the sensitivity of U87-R glioma cells to TMZ by targeting miR-126-5p and activating Wnt/β-catenin signaling (82). It has also been previously reported that EGFR signaling plays a key role in GBM (85), by regulating lncRNA nuclear enriched abundant transcript 1 (NEAT1) expression and in turn promoting glioma cell growth by targeting the Wnt/β-catenin pathway. Taken together, these results suggest that NEAT1 is a potential therapeutic target in GBM (86).

p21/Notch pathway. TMZ has been shown to induce GBM cell senescence and autophagy, which promote GBM cell survival without affecting proliferation (87). TMZ-induced senescence has been found to be dependent on p21 activity. GSCs are a main cause of TMZ resistance. MMP14 is an enzyme that is localized to the cell membrane (88). It was previously reported that TMZ treatment increased MMP14 expression in GSCs, which activated Notch signaling (89). In another study, the expression of IncRNA LINC00021 was revealed to be markedly upregulated in TMZ-resistant GBM cells, and the silencing LINC00021 expression promoted TMZ sensitivity, whilst suppressing the apoptosis of TMZ-resistant cells (75). Additionally, the expression of p21 was found to be downregulated by LINC00021 by targeting EZH2. Western blot analysis revealed that LINC00021 knockdown inhibited Notch expression. Therefore, LINC00021 was concluded to promote the malignant features of GSCs and the chemoresistant phenotype through the p21/Notch axis (75).

EMT signaling pathway. EMT has been observed to not only promote cell migration, but also chemoresistance in tumor cells. Wen et al (90) reported that the expression of EMT markers was upregulated in oxalipatin-resistant human gastric cancer cell lines. In addition, EMT has been found to be associated with the resistance of pancreatic cancer to treatment (91). In another study, Peng et al (92) discussed that EMT can be regulated through miRNAs and summarized a list of drug candidates that may suppress EMT in cancer. EMT was also identified to be part of the mechanism underlying cancer resistance to EGFR tyrosine kinase inhibitors in both mouse models and in clinical non-small cell lung cancer (NSCLC) specimens (92). However, the effects of EMT on TMZ resistance in glioma cells remain unclear and require further investigation. Previously, a novel IncRNA TCONA_00004099 was identified through the analysis of sequencing data, the expression levels of which were high in glioma tissues and cell lines (79). In both in vitro and in vivo models, TCONA_00004099 knockdown was found to inhibit glioma progression and promote TMZ-induced U87 and U251 cell apoptosis. This mechanism of resistance associated with TCONA_00004099 in glioma was then examined using miRNA mimics. TCONA_00004099 was demonstrated to sponger the miRNA TCONA_00004099 and its target protein tyrosine phosphatase, receptor type F, which is involved in EGF signaling (79). Therefore, these findings reveal potentially novel therapeutic targets for TMZ-resistant glioma. IncRNA EGFR-AS1 was previously observed to promote the proliferation, migration and invasion, whilst inhibiting the apoptosis of glioma cells by regulating miR-133b/ribosomal receptor for activated C-kinase 1 (RACK1) (80). However, the effects of Inc-EGFR-AS1 on the sensitivity of GBM cells to TMZ requires further investigation both in vivo and in vitro (80). IncRNA HOTTIP expression was reported to be significantly elevated in SF268 glioma cells, particularly resistant to TMZ (93). Moreover, the expression of miR-10b and the mesenchymal markers, ZEB1/ZEβ2, was increased, while the expression of E-cadherin was decreased in SF268, indicating that EMT plays a crucial role in TMZ resistance. Moreover, EMT was reversed in HOTTIP overexpressing cell lines by silencing miR-10b. Thus, HOTTIP regulated TMZ resistance in glioma cells via the EMT signaling pathway by targeting miR-10b (93).

FGFR3, platelet-derived growth factor receptor (PDGFR) and EGFR have all been found to be among the upregulated receptor tyrosine kinases involved in GBM tumorigenesis (94,95), which are also associated with the EMT process. The expression profile of FGFR3 was consistent with that of EGFR, whereby FGFR inhibition enhanced NSCLC sensitivity to EGFR inhibitors (96). Furthermore, PDGFR was found to promote the EMT process in glioma by promoting ZEB1 expression, an inducer of EMT (97). Cui et al (76) previously reported that IncRNA colon cancer-associated transcript 1 (CCAT1) expression was increased in glioma tissues, whilst that of miR-181b was downregulated. CCAT1 silencing was observed to significantly suppress the malignant biological behavior of glioma cells, which was reversed with miR-181b inhibitors. In addition, CCAT1 was found to function as a ceRNA with miR-181b to promote the expression of FGFR3 and PDGFR. Collectively, CCAT1 downregulation suppressed glioma growth by targeting miR-181b, resulting in the downregulation of the endogenous targets, FGFR3 and PDGFR (76). However, the effects of CCAT1 on the resistance of gliomas to TMZ and EMT require further in vivo and in vitro investigations.

p38/MAPK pathway. The function of p38 MAPK signaling is to relay extracellular stimuli through the cell (98). The activation of the p38 MAPK pathway has been reported to promote glioma invasiveness (99). Nuclear transcription factor erythroid 2p45 (NF-E2)-related factor 2 (Nrf2) has also been shown to promote the resistance of glioma cells to the combined treatment of TMZ and radiotherapy (100). In addition, another previous study found that TMZ increased Nrf2 phosphorylation of p38 MAPK. Furthermore, C5/C5a can promote glioma invasiveness (101). The role of Inc-TALC in promoting the resistance of GBM to TMZ has been observed. Furthermore, Inc-TALC can be incorporated into exosomes and exported to tumor-associated macrophages to promote M2 polarization. M2 macrophage polarization has been shown to be associated with the secretion of complement components C5/C5a, which occurs after the binding of Inc-TALC to enolase 1 to promote the phosphorylation of p38 MAPK. Furthermore, C5/C5a can promote the resistance to chemotherapy of GBM. Taken together, Inc-TALC can potentially regulate the microenvironment of GBM to improve GBM resistance to TMZ chemotherapy through the p38 MAPK pathway (70).
PTEN/PI3K/Akt pathway. PTEN is a protein phosphatase that targets the lipid phosphatidylinositol-3,4,5-triphosphate (PIP3), which is the product of PI3K. PTEN mutation and PI3K activation promote the accumulation of PIP3, resulting in the activation of AKT (102). PI3K/AKT signaling activation is associated with the expression of MGMT, the main factor of TMZ resistance. Supporting this, the pan-PI3K inhibitor, PX-866, has been found to block TMZ-induced autophagy, whilst promoting GBM cell death (103). In addition, the activation of PTEN/PI3K/AKT signaling has been reported to be an essential step in the development of TMZ resistance in GBM cells in a MGMT-dependent manner (104-106).

In glioma tissues and cells resistant to TMZ, the expression of the lncRNA musculin antisense RNA1 (MSC-ASI) has been demonstrated to be increased. MSC-ASI1 knockdown has been shown to induce cell apoptosis and promote TMZ sensitivity by targeting the PI3K/AKT pathway (65). Cytoplasmic polyadenylation element binding protein (CPEB4) is an RNA-binding protein that participates in autophagy. The increased expression of CPEB4 has been found to be associated with migration, tumor growth, angiogenesis, metastasis and invasion (66). Additionally, the suppression of IncRNA-forhead box D2-antisense RNA1 (FoxD2-ASI) expression has been found to inhibit the invasion, proliferation, migration and of TMZ-resistant glioma cells by promoting miR-98-5p expression, which inhibits CPEB4 expression (67). These data suggest that FoxD2-ASI1 can inhibit glioma chemoresistance to TMZ by modulating the miR-98-5p/CPEB4 axis (58). Furthermore, the expression of CPEB4, as a target of miR-373-3p, was also found to be regulated by MSC-ASI. Specifically, MSC-ASI1 knockdown inhibited the malignant behavior of glioma cells and increased their sensitivity to TMZ by sponging miR-373-3p, which activated the PI3K/Akt pathway both in vitro or in vivo (65). Similarly, the expression of the non-catalytic region of tyrosine kinase adaptor protein 1-antisense RNA1 was reported to be increased in glioma tissues and cells resistant to TMZ, which facilitated the resistance to TMZ by activating the miR-137/tripartite motif containing 24 pathways (81). In addition, in a previous study, the expression of the IncRNA LINC01410 was found to be upregulated in GBM and in GBM cells resistant to TMZ. LINC01410 silencing promoted the sensitivity of TMZ-resistant cells whilst also upregulating the expression of PTEN but reducing the phosphorylation of AKT. Inhibition of miR-370-3p reversed the effects of LINC01410 silencing on the malignant biological behavior of GBM cells. Based on these findings, LINC01410 was concluded to promote glioma growth and TMZ resistance by sponging miR-370-3p to inhibit the PTEN/AKT pathway (62).

p53 signaling. p53 is a key transcription factor that can regulate the transcription of target genes in response to DNA damage. p53 suppresses the gene expression of O6-alkylguanine DNA alkyltransferase. In addition, Y-box binding protein 1 and mouse double minute 2 homolog were found to be overexpressed in glioma cells and were previously found to be associated with TMZ resistance by directly targeting p53 (107,108). Therefore, p53 may be associated with the resistance of glioma cells to TMZ.

The levels of IncRNA brain cytoplasmic RNA1 (BCYRN1) were previously found to be increased in the blood and tumor tissues from patients with GBM. Furthermore, the expression of BCYRN1 differed significantly from that of isocitrate dehydrogenase 1 (IDH1) and the p53 status and was markedly higher compared with both p53 and Ki-67 expression. The silencing of BCYRN1 expression was previously reported to inhibit the proliferation, migration, invasion and reverse resistance to TMZ in GB cells by sponging miR-218-5p (68).

Compared with normal tissues, higher expression levels of IncRNA CCAT2 were previously found in glioma tissues and cells and were found to negatively correlate with those of miR-424 (69). In addition, different glioma cell lines exhibited varying degrees of resistance to chemotherapeutic agents. Specifically, SHG44 was the most resistant cell line whereas U251 cells were more sensitive to agents, such as TMZ. However, regardless of the cell line tested, the knockdown of CCAT2 expression or the overexpression of miR-424 markedly inhibited the proliferation, invasion and migration of glioma cells (69). Furthermore, checkpoint kinase 1 (CHK1), which is activated by DNA damage, was reported to be a target of miR-424. The overexpression of CHK1 reversed the effects of miR-424 overexpression in both p53 wild-type and p53 mutant glioma cells (109). Taken together, these findings suggest that IncRNA CCAT2 expression is upregulated in glioma tissues and cells, which in turn promotes tumor growth and resistance to TMZ possibly through the miR-424/CHK1 axis (69).

PIM1/survivin pathway. PIM1 is a serine/threonine kinase that plays a key role in promoting cell proliferation and conferring chemoresistance in various malignancies, such as prostate cancer, HER2-positive breast cancer, high-risk neuroblastoma, triple negative breast cancer and so on (110-113). The expression of survivin can be decreased by the MGMT inhibitor (114). In addition, TMZ-induced senescence results in tumor cell cycle arrest, promoting TMZ resistance. Song et al (115) previously indicated that the knockdown of survivin promoted glioma cell sensitivity to TMZ treatment by inducing the apoptosis of senescent cells. Furthermore, survivin nuclear trapping has been found to facilitate GBM response to TMZ (116).

The IncRNA potassium voltage-gated channel subfamily Q member 1 opposite strand/antisense transcript one gene (KCNYQIOT1) was previously reported to promote the proliferation and colony formation of glioma cells by negatively regulating miRNA-761 expression. It was also found to impair the effects of TMZ on the promotion of the apoptosis of glioma cells in vitro. Furthermore, the overexpression of KCNYQIOT1 was found to increase survivin expression by promoting PIM1 expression in glioma cells. In vivo, the experimental results were consistent with their in vitro counterparts. Taken together, it was found that IncRNA KCNYQIOT1 played a significant role in glioma sensitivity to TMZ by sponging miR-761 to activate PIM1/survivin signaling, which may be exploited as a potential prognostic target (78).

Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling pathway. Over the past decade, immune checkpoint inhibitors have become a topic of extensive research for tumor treatment. Among these, PD-1/PD-L1 have been found to exert promising therapeutic
effects against various malignancies. PD-L1 has also been shown to be strongly expressed in a wide range of tumor cells, including breast cancer, oral squamous cell carcinoma and nasopharyngeal carcinoma (117-119). The PD-1/PD-L1 signaling pathway plays a constructive role in tumor immunosuppression by inducing T-cell death and activating tumor immune escape (120).

Furthermore, several studies have demonstrated that a number of lncRNAs are associated with PD-1/PD-L1 in different types of cancer (Fig. 1). A previous study demonstrated that human antisense lncRNA-NK-2 homeobox 1 antisense RNA1 (NKX2-1-AS1) negatively regulated the expression of endogenous CD274/PD-L1, and that NKX2-1-AS1 knockdown was able to upregulate the expression of genes that are involved in cell adhesion and checkpoints (121). In addition, PD-1/PD-L1 was found to exert promoting effects on diffuse large-B-cell lymphoma (DLBCL), and lncRNA SNHG14 expression negatively correlated with miR-152-3p, the expression of which was decreased in DLBCL tissues and cell lines. Furthermore, SNHG14/miR-152-3p inhibited apoptosis and promoted cell proliferation in cytotoxic T-lymphocytes (CTLs) in DLBCL by sponging the PD-1/PD-L1 checkpoint (122).

Similarly, SNHG15 lncRNA, which is highly expressed in gastric cancer cells, was reported to increase the expression of PD-L1 (123). Zhou et al (124) found that in pancreatic cancer tissues and cell lines, the expression of LINC00473 was increased, whilst that of miR-195-5p was decreased, and the expression of PD-L1 was increased. Mechanistically, LINC00473 upregulated PD-L1 expression by targeting miR-195-5p. Furthermore, CD8+ T-cells could be activated either by the silencing of LINC00473 expression or increasing miR-195-5p expression, which inhibited PC progression (124).

In addition to these aforementioned pre-clinical findings, a database analyses have also revealed the potential of lncRNAs in regulating PD-1/PD-L1 signaling. According to The Cancer Genome Atlas-liver hepatocellular carcinoma (HCC) dataset, PC-esterase domain-containing 1B-antisense RNA1 promoted PD-L1 and PD-L2 expression by inhibiting hsa-miR-194-5p expression, resulting in immunosuppression in HCC (125). Similarly, the association between lncRNA-myocardial infarction associated transcript (MIAT) and immunomodulatory regulation in HCC was also investigated. The results revealed that the expression of MIAT in HCC was positively associated with that of PD-1/PD-L1. Furthermore, MIAT reduced the sensitivity of HCC to sorafenib, an anticancer drug, mediating immune escape (126).

Previous studies have demonstrated that various lncRNAs can regulate the PD-1/PD-L1 axis in gliomas. The lncRNA interferon (IFN)-stimulated non-coding RNA 1 (INCR1) can be transcribed from the PD-L1 locus following stimulation by tumor IFNs and can promote checkpoint blockade resistance in GBM. INCR1 knockdown was found to inhibit PD-L1
expression and enhance GBM cell sensitivity to cytotoxic T-cell-mediated cell death (127). Mechanistically, INCR1 was found to promote the expression of PD-L1 genes by binding to heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1), a nuclear ribonucleoprotein, to negatively regulate the transcription of PD-L1. In summary, INCR1 IncRNA can regulate PD-L1 expression and responses to immune checkpoint therapy by targeting HNRNPH1 after IFNγ signaling (127). Similarly, the IncRNA HOTAIR was also found to be highly expressed in glioma cells (77). Bioinformatics analysis revealed that HOTAIR activated the expression of proteins in the NF-κB signaling pathway. Furthermore, the downregulation of HOTAIR expression was found to inhibit PD-L1 expression in vivo, suggesting that HOTAIR can improve the sensitivity of glioma cells to immune checkpoint inhibitor therapy. In summary, HOTAIR positively regulated PD-L1 expression by targeting the NF-κB signaling pathway in gliomas (77). According to the existing public bioinformatics database, higher levels of the IncRNA MIR155HG have been shown to be associated with a poorer overall survival of patients with GBM. In addition, the levels of MIR155HG expression have been demonstrated to be significantly consistent with those of PD-L1, suggesting that MIR155HG can be used predict the efficacy of immune checkpoint inhibitor therapy (63). Taken together, IncRNAs may represent a therapeutic target that can regulate the effects of PD-1/PD-L1 treatment in various types of cancer, particularly gliomas. However, T-cells in GBM are very unresponsive to immunotherapy, and PD-1 checkpoint blockade cannot be overcome through intracellular regulation. Further research on combination therapy is still in progress (128). Due to chemo-immunotherapy resistance, Miyazaki et al (129) used a TMZ-treated glioma model to examine the effects of anti-PD-L1 antibody on the tumor microenvironment. They also established TMZ-resistant TS (TMZRTS) cells to examine the effects of anti-PD-L1 antibody on glioma growth. The results of their study revealed that anti-PD-L1 antibody significantly suppressed tumor growth and markedly decreased CD163-positive M2 infiltration into tumors. However, the safety and effectiveness of clinical therapy need to be further studied (129). Nivolumab is a type of PD-1 inhibitor. Recent research has reported that a patient with GBM received nivolumab treatment for almost 2 years following standard radiotherapy and TMZ therapy. Magnetic resonance imaging revealed a continuous shrinking of the tumor (130), suggesting that the combined application with PD-1 inhibitor may be effective for the treatment of gliomas. Clinically, TMZ is used as an adjuvant therapy for patients with glioma, while the prognosis is poor. Thus, exploring the role of PD-1/PD-L1 combined with TMZ is of therapeutic significance. Notably, it was demonstrated that stereotactic radiation, which to date is a conventional treatment for glioma, combined with anti-PD-1 blockade enhanced the long-term survival rate of tumor-bearing mice (131), which provided further evidence of the potential of combining TMZ with PD-1 inhibitors. In a previous clinical study, 47 patients were divided into two subgroups (132). One subgroup of 27 patients, which was named as ADCTA, was treated with concomitant chemo-radiotherapy (CCRT). Moreover, the patients also received post-surgical adjuvant immunotherapy with an autologous dendritic cell/tumor antigen vaccine. The other subgroup was only treated with CCRT and TMZ without immunotherapy as the control group. The results of that study demonstrated that the ADCTA group exhibited a markedly low TIL PD-1+CD8+ ratio within the GBM tumor compared with the control group, which prolonged the overall survival rate of the patients. On the whole, that study suggested that adjuvant immune therapy for the immune system combined with conventional therapies, such as TMZ, has great potential for the treatment of GBM (132). In conclusion, the combination of immune checkpoint inhibitors and anti-tumor chemical drugs, such as TMZ, has a promising therapeutic effect on glioma, which further provides new insight into the treatment of gliomas in clinical practice.

4. Tumor suppressive IncRNAs influence the sensitivity of gliomas to TMZ

The expression of a number of tumor suppressor IncRNAs (Table II) has been found to be downregulated in gliomas compared with normal brain tissues (38). The re-expression of these tumor suppressor IncRNAs can enhance the therapeutic effects of TMZ by regulating the mTOR, PTEN/AKT and p53/NF-κB signaling pathways.

mTOR signaling pathway. mTOR is a serine/threonine kinase that can regulate cell proliferation (133). Tomar et al (83) previously observed that mTOR signaling was activated following TMZ treatment. A novel inhibitor (Rapalink-1) targeting the mTOR pathway was previously identified to function synergistically with TMZ to reduce cell proliferation (134). Autophagy is a process that has been previously associated with TMZ resistance. Zou et al (135) reported that the upregulation of autophagy was mediated by transient receptor potential cation channel subfamily C member 5 in glioma cells, which promoted TMZ resistance through the mTOR signaling pathway. Based on this finding, it can be hypothesized that the mTOR pathway is associated with autophagy, thereby affecting TMZ resistance.

In vitro, the expression of the IncRNA cancer susceptibility candidate 2 (CASC2) was found to be decreased in glioma tissues and cell lines, the upregulation of which was associated with a longer survival time (136). Clinically, TMZ treatment significantly inhibited glioma proliferation, whilst the upregulation of CASC2 expression resulted in the opposite effect. Furthermore, a downstream target of CASC2 was determined to be miR-193a-5p, with which negatively correlated (136). In TMZ-resistant glioma cells, CASC2 upregulation impaired autophagy, which was reduced by TMZ by inhibiting miR-193a-5p expression, thereby activating the mTOR pathway. These data suggest that upregulating the expression of CASC2 may be a potential therapeutic target for patients with TMZ-resistant glioma. However, further clinical trials are required to examine the feasibility of this target (136).

IncRNA growth arrest specific 5 (GAS5) has been reported to play a constructive role in various tumor types, such as gastric cancer and NSCLC. It has been observed to inhibit the proliferation, migration and invasion of human glioma cells by targeting miR-18a-5p or miR-196a-5p (137,138). In addition, GAS5 can reverse glioma cell resistance to cisplatin by preventing excessive autophagy through activation of mTOR.
signaling (139). Similarly, in another previous study (140), which investigated the U251 and U87 cell lines, the expression of GAS5 was found to be decreased, and the upregulation of GAS5 was able to inhibit tumor growth by sponging glutathione-S-transferase M3, the overexpression of which has been associated with chemoresistance. However, the effects of GAS5 on the resistance of glioma cells to TMZ require further examination in vitro and in vivo (140).

PTEN/p-AKT pathway. IncRNAs can also regulate resistance to TMZ by targeting the PTEN, p53 and PI3K/AKT/mTOR pathways (141). In a previous study, the overexpression of IncRNA CASC2 was found to reverse the resistance of glioma cells to TMZ by inhibiting miR-181a expression (142). In addition, CASC2 promoted PTEN protein expression and inhibited AKT phosphorylation by targeting miR-181a in a reversible manner by miR-181a overexpression. Therefore, CASC2 may be a clinically relevant IncRNA that can mediate TMZ resistance by regulating miR-181a expression (142).

p53/NF-κB pathway. NF-κB is a transcription factor and plays a key role in cell survival, inflammation and immune responses. In particular, NF-κB has been found to be associated with cellular senescence in response to chemotherapy. Accordingly, senescence induced by chemotherapy and mediated by NF-κB is a key characteristic of superior therapeutic outcomes (143). Therefore, NF-κB will likely affect TMZ resistance by modulating cellular senescence.

The p53-regulated tumor suppressor signature of IncRNAs (PR-IncRNAs) was first identified in colorectal cancer (144). In glioma, the expression of PR-IncRNAs was found to be negatively associated with its grade (145). A previous functional study reported that PR-IncRNA knockdown aggravated glioma malignancy by inhibiting SOX activity. This suggests that the downregulation of PR-IncRNAs can abrogate the beneficial effects of PR-IncRNAs on cell proliferation, migration, invasion and resistance to TMZ in vitro (145). Similarly, the expression of leukemia inhibitory factor receptor-antisense RNA1 (LIFR-AS1) has also been found to be decreased, whereas that of miR-4262 was found to be increased in glioma tissues and cell lines. The overexpression of LIFR-AS1 inhibited glioma cell proliferation and enhanced glioma cell sensitivity to TMZ by inactivating the miR-4262/NF-κB pathway (146). IncRNA-zinc finger protein 281 (ZNF281) was previously reported to be expressed at lower levels in glioma stem-like cells (U251s) compared with those in normal brain tissues. Furthermore, IncRNA-ZNF281 was able to suppress the self-renewal capacity and invasion of glioma stem cells by activating the NF-κB signaling pathway in vitro and in vivo (147).

The various mechanisms of IncRNAs in the regulation of TMZ resistance in glioma are illustrated in Fig. 2.

5. Conclusions and future perspectives

GBM, which is considered to originate from neural stem cells or progenitors, remains to be one of the greatest threats to human health to date. Regrettably, even with the traditional treatment methods of gliomas, including surgery, radiation therapy and alkylating agent chemotherapy, such as TMZ, the overall survival of patients with gliomas has not improved satisfactorily (148). Additionally, >50% patients with glioma treated with TMZ develop resistance to this drug, which has become a major obstacle in the clinical treatment efficacy of glioma (9). Apart from DNA repair systems, the mechanism underlying chemotherapy resistance also included translesion synthesis (TLS). When DNA lesions occur due to chemotherapy and/or radiation, such as following treatment with

| IncRNA   | Cell lines | Targets/ regulators | Signaling pathways | Functional impact | (Refs.) |
|----------|------------|---------------------|--------------------|------------------|--------|
| CASC2    | -          | miR-181a/miR-193a-5p| PTEN/p-AKT         | Impairs TMZ resistance and proliferation of glioma. | (131,137) |
| GAS5     | U251/U87   | miR-18a-5p/miR-196a-5p| mTOR               | Suppresses the proliferation, migration, and invasion of humanglioma cells; attenuates gliomacell resistance | (132,135) |
| ZNF281   | U251s      | -                   | NF-κB1             | Suppresses the self-renewal capacity and invasion of glioma stem-like cells | (139) |
| PR-LncRNA| -          | SOX                 | p53                | Inhibits the malignant behavior of glioma cells | (139) |
| LIFR-AS1 | -          | miR-4262            | NF-κB              | Inhibits glioma cell growth and enhance glioma cell sensitivity to TMZ | (140) |

IncRNAs, long non-coding RNAs; TMZ, temozolomide; CASC2, cancer susceptibility candidate 2; GAS5, growth arrest specific 5; ZNF281, zinc finger protein 281; LIFR-AS1, leukemia inhibitory factor receptor-antisense RNA1.
cisplatin and TMZ, TLS can bypass these types of lesions at the cost of increasing the risk of mutations (149), which in turn increases the risk of developing chemotherapeutic resistance. The TLS process involves several key regulators, including RAD18 (150), DNA polymerases (POL\(\kappa\), POL\(\iota\), POL\(\eta\)) or REV1 (which introduce a nucleotide opposite the lesion) and TLS DNA polymerase, such as POL\(\zeta\) (comprising of the Rev3L/Rev7/Pold2d/Pold3 complex) (149,151). Peng et al (152) previously reported that the overexpression of POL\(\kappa\) increased the TMZ resistance of GBM cells which were previously TMZ-sensitive. The higher expression of POL\(\kappa\) significantly promoted TMZ sensitivity in vitro and in orthotopic xenograft mouse models. Furthermore, other TLS polymerases, such as Rev1 and Rev7, have been proposed as targets for developing agents for reversing chemoresistance (151,153). RAD18 was previously found to be overexpressed in GBM cell lines, where it promoted resistance to radiotherapy by inhibiting the expression of p53 (154).

lncRNAs have been demonstrated to regulate the survival, proliferation, apoptosis and invasion of GBM cells (155). Furthermore, IncRNAs play a key role in regulating the resistance of gliomas to TMZ by sponging miRNAs and various signaling pathways. However, TMZ can conversely regulate the levels of lncRNA expression to enhance the effectiveness of TMZ treatment. Recently, lncRNA ATXN8OS was found to be mainly located in the cytoplasm and to be downregulated in glioma cell lines (156). Functional experiments proved that ATXN8OS enhanced TMZ sensitivity of glioma in vivo and in vitro. Mechanistically, ATXN8OS stabilized glutaminase 2 mRNA to promote the ferroptosis of glioma cell lines, which may become a new target of TMZ resistance (154). High mobility group box 1 protein (HMGB1), which is a highly conserved protein, has been reported to be expressed in a variety of cell types and can be secreted into the tumor microenvironment to function as a tumor-derived signal. HMGB1 expression has been found to be upregulated in GBM and to
influence GBM growth. GSCs play a crucial role in patients with TMZ-resistant glioma, and HMGB1 expression has been found to be upregulated in GSCs (157). HMGB1 can then alter the expression profile of mRNAs, lncRNAs and miRNAs in GSCs. Since TMZ-induced HMGB1 expression can promote the formation of GSCs, this process is inhibited when the secretion of HMGB1 is decreased. In terms of the mechanism, TMZ-induced upregulation of HMGB1 has been found to promote the formation of GSCs through the Toll-like receptor 2/NEAT1/Wnt pathway. Taken together, TMZ-induced HMGB1 may serve as a potential therapeutic target for the treatment of patients with TMZ-resistant GBM (157). In addition, a number of traditional Chinese medicine ingredients have also been reported to affect TMZ resistance by regulating the expression of lncRNAs. Isoliquiritigenin has been found to inhibit the expression of metabolic enzymes of arachidonic acid (AA), such as cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1) and cytochrome P450 (CYP) 4A11, all of which serve significant roles in glioma angiogenesis. Furthermore, isoliquiritigenin can enhance the therapeutic effects of TMZ in a rat C6 glioma model. In terms of the mechanism, isoliquiritigenin can reprogram COX-2, mPGES-1- and CYP4A-mediated AA metabolism in glioma by suppressing angiogenic Akt/fibroblast growth factor 2/TGFβ/VEGF signaling, which was achieved by sponging miR-194-5p and lncRNA NEAT1 (158). To conclude, lncRNAs may serve as potential therapeutic and prognostic targets to improve the sensitivity of glioma to TMZ. However, enormous research efforts remain necessary to transform this basic concept into a feasible clinical strategy.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 82003879 and U19A2010) the Key Project of Science and Technology Department of Sichuan Province (grant nos. 2020YS0053 and 2021YS0044), and the Youth Talent Promotion Project of China Association for Science and Technology (grant no. CACM-2020-QNRC1-01) and the Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China (grant no. 2021LF1026).

Availability of data and materials

Not applicable.

Authors’ contributions

The present review article was conceptualized by all the authors (SL, XX, FP, JD and CP). SL was involved in the study design and in the preparation of the original draft. FP, XX and JD edited the manuscript. FP, JD and CP were involved in funding-related administration. SL and FP were involved in manuscript revision. All authors have read and agreed to the published version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 131: 803-820, 2016.
2. Wynne-Edwards R, Silmi A, Violeau C, Leriche F, Chaurin C: Temozolomide and beta-catenin expression in glioblastoma multiforme. J Neurooncol 77: 295-302, 2006.
3. Stupp R, Mason WP, van den Bent MJ, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: The effects of bevacizumab on the survival of patients with glioblastoma: A randomized clinical trial. JAMA 318: 2306-2316, 2017.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
5. Strobel H, Baisch T, Fitzek R, Schilberg K, Siegel M, Kranzpel-Massler G, Debatin KM and Westhoff MA: Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines 7: 69, 2019.
6. Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102-114, 2012.
7. Stupp R, Brada M, van den Bent MJ, Voss J and Pentheroudakis G: ESMO Guidelines Working Group: High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (Suppl 3): iii93-iii101, 2014.
8. Lee SY: Temozolomide resistance in glioblastoma multiforme. Genes Dis 3: 198-210, 2016.
9. Kanzawa T, Bedwell J, Kondo Y, Kondo S and Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99: 1047-1052, 2003.
10. Jiang G, Li LT, Yin X, Zhang L, Liu QY and Zheng JN: Strategies to improve the killing of tumors using temozolomide: Targeting the DNA repair protein MGMT. Curr Med Chem 19: 3868-3892, 2012.
11. Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gonzalez B and Melguizo C: Temozolomide resistance in glioblastoma cell lines: Implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One 10: e0140131, 2015.
18. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, 30. Ye X, Wang LP, Han C, Hu H, Ni CM, Qiao GL, Ouyang L
17. Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, 23. Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, Zhang A, Jia Z, 29. 35. Li DQ, Ding YR, Che JH, Su Z, Yang WZ, Xu L, Li YJ, Wang HH
14. ENCODE Project Consortium: An integrated encyclopedia of 19. Wang G, Yu S, Zeng T and Ling H: lncRNAs as hallmarks for individualized treatment of gastric cancer. Anticancer Agents Med Chem 22:
12. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, 396‑406, 2019.
15. Jiang Y, Guo H, Tong T, Xie F, Qin X, Wang X, Chen W and 41. Wang X, Li XD, Fu Z, Zhou Y, Hu H, Li H and Xu C: LncRNA PVT1 contributes to the development and disease. Cell Mol Life Sci 73: 2491‑2509, 2016.
14. ENCODE Project Consortium: An integrated encyclopedia of 20. Yu B and Wang S: Angio‑LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics 8: 3654‑3675, 2018.
16. Wilusz JE, Sunwoo H and Spector DL: Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev 23: 1494‑1500, 2009.
20. Yu B and Wang S: Angio‑LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics 8: 3654‑3675, 2018.
18. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, 30. Ye X, Wang LP, Han C, Hu H, Ni CM, Qiao GL, Ouyang L
17. Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, 23. Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, Zhang A, Jia Z, 29. 35. Li DQ, Ding YR, Che JH, Su Z, Yang WZ, Xu L, Li YJ, Wang HH
14. ENCODE Project Consortium: An integrated encyclopedia of 19. Wang G, Yu S, Zeng T and Ling H: lncRNAs as hallmarks for individualized treatment of gastric cancer. Anticancer Agents Med Chem 22:
12. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, 396‑406, 2019.
15. Jiang Y, Guo H, Tong T, Xie F, Qin X, Wang X, Chen W and 41. Wang X, Li XD, Fu Z, Zhou Y, Hu H, Li H and Xu C: LncRNA PVT1 contributes to the development and disease. Cell Mol Life Sci 73: 2491‑2509, 2016.
14. ENCODE Project Consortium: An integrated encyclopedia of 20. Yu B and Wang S: Angio‑LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics 8: 3654‑3675, 2018.
16. Wilusz JE, Sunwoo H and Spector DL: Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev 23: 1494‑1500, 2009.
20. Yu B and Wang S: Angio‑LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics 8: 3654‑3675, 2018.
18. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, 30. Ye X, Wang LP, Han C, Hu H, Ni CM, Qiao GL, Ouyang L
17. Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, 23. Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, Zhang A, Jia Z, 29. 35. Li DQ, Ding YR, Che JH, Su Z, Yang WZ, Xu L, Li YJ, Wang HH
14. ENCODE Project Consortium: An integrated encyclopedia of 19. Wang G, Yu S, Zeng T and Ling H: lncRNAs as hallmarks for individualized treatment of gastric cancer. Anticancer Agents Med Chem 22:
12. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, 396‑406, 2019.
15. Jiang Y, Guo H, Tong T, Xie F, Qin X, Wang X, Chen W and 41. Wang X, Li XD, Fu Z, Zhou Y, Hu H, Li H and Xu C: LncRNA PVT1 contributes to the development and disease. Cell Mol Life Sci 73: 2491‑2509, 2016.
14. ENCODE Project Consortium: An integrated encyclopedia of 20. Yu B and Wang S: Angio‑LncRs: LncRNAs that regulate angiogenesis and vascular disease. Theranostics 8: 3654‑3675, 2018.
16. Wilusz JE, Sunwoo H and Spector DL: Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev 23: 1494‑1500, 2009.
75. Zhang S, Guo S, Liang C and Lian M: Long intergenic noncoding
74. Zhou L, Huang X, Zhang Y, Wang L, Li H and Huang H:
78. Wang W, Han S, Gao W, Feng Y, Li K and Wu D: Long noncoding
73. Jiang P, Wang P, Sun X, Yuan Z, Zhan R, Ma X and Li W:
69. 
67. Gu N, Wang X, Di Z, Xiong J, Ma Y, Yan Y, Qian Y, Zhang Q
65. Li C, Feng S and Chen L: MSC‑AS1 knockdown inhibits
58. Miyazawa K and Miyazono K: Regulation of TGF‑
72. 
61. Nie E, Jin X, Miao F, Yu T, Zhi T, Shi Z, Wang Y, Zhang J, Xie M and You Y: TGF‑β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. Neuro Oncol 23: 435‑446, 2021.
70. Li Z, Meng X, Wu P, Zha C, Han B, Li L, Sun N, Qi T, Qin J, You Y: LINC00511 facilitates glioma metastasis via Wt‑catenin signaling. Ann Transl Med 9: 1023, 2021.
89. Tomar VS, Patil V and Somasundaram K: Temozolomide decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial‑mesenchymal transition via the TGF‑β/cathepsin K axis. Front Oncol 12: 873561, 2022.
90. Ding J, Zhang L, Chen S, Cao H, Xu C and Wang X: IncRNA CCAT2 enhanced resistance of glioma cells against chemotherapies by disturbing the normal function of miR‑424. Onco Targets Ther 13: 1431‑1445, 2020.
91. Li Z, Meng X, Wu P, Zha C, Han B, Li L, Sun N, Qi T, Qin J, Zhang Y et al: Glioblastoma cell‑derived IncRNA‑containing exosomes induce microglia to produce complement C5, promoting chemoresistance and therapy resistance. Cancer Immunol Res 9: 1383‑1390, 2021.
92. Li B, Zhao H, Song J, Wang F and Chen M: LINC00174 down‑regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR‑138‑5p/SOX9 axis. Hum Cell 33: 159‑174, 2020.
93. Jia L, Tian Y, Chen Y and Zhang G: The silencing of LncRNA‑H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial‑mesenchymal transition via the TGF‑β‑catenin pathway. Onco Targets Ther 11: 313‑321, 2018.
94. Jiang P, Wang P, Sun X, Yuan Z, Zhan R, Ma X and Li W: Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. Onco Targets Ther 9: 3501‑3506, 2016.
95. Zhan L, Huang X, Zhang Y, Wang L, Li H and Huang H: PSMG3‑AS1 enhances glioma resistance to temozolomide via stabilizing c‑Myc in the nucleus. Brain Behav 12: e2531, 2021.
96. Zhang S, Guo S, Liang C and Lian M: Long intergenic noncoding RNA 000499‑derived microRNA regulates oncogenesis through PTPTR in gliomas. Ann Transl Med 9: 1023, 2021.
97. Yang Q, Guo ZY, Wang Y, Zhang S and Lian M: The IncRNA EFRG‑AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR‑133b/RACK1. Biomed Pharmacother 118: 109292, 2019.
98. Chen M, Cheng Y, Yuan Z, Wang F, Yang L and Zhao H: NCK1‑AS1 increases drug resistance of glioma cells to temozolomide by modulating miR‑137‑3p/TRIM24. Cancer Biother Radiopharm 35: 101‑108, 2020.
99. Liu Y, Tian M, Liu J and Wang K: LINC00511 facilitates temozolomide resistance of glioblastoma cells via sponging Wnt‑β‑catenin signaling. J Biochem Mol Toxicol 35: e228414, 2021.
100. Tomar VS, Patil V and Somasundaram K: Temozolomide induces activation of Wt‑catenin‑signaling in glioma cells via PI3K/Akt pathway: Implications in glioma therapy. Cell Biol Toxicol 36: 273‑278, 2020.
101. Liu H, Liu Z, Jiang B, Peng R, Ma Z and Lu J: SOX9 overexpression promotes glioma metastasis via Wt‑catenin‑signaling pathway. Cell Biophys Biochem 73: 205‑212, 2015.
102. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanbourn JZ, Emanuel SH et al: The somatic genomic landscape of glioblastoma. Cell 155: 462‑477, 2013.
103. Chen Q, Cai J, Wang Q, Wang Y, Liu M, Yang J, Zhou J, Kang C, Li M and Jiang C: Long noncoding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/β‑catenin pathway by scaffolding EZH2. Clin Cancer Res 24: 684‑695, 2018.
104. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Christmann M and Kaina B: Survival and death strategies in glioma cells: Autophagy, senescence and apoptosis triggered by a single type of temozolomide‑induced DNA damage. PLoS One 8: e55665, 2013.
105. Linder S, Wiesner C and Himmel M: Degrading devices: Invasodromes in proteolytic cell invasion. Annu Rev Cell Dev Biol 27: 185‑211, 2011.
106. Ulasov IV, Mijanovic O, Savchuk S, Gonzalez‑Buendia E, Sonabend A, Xiao T, Timashev P and Lenski MS: TMZ regulates GBM stenness via MMP14‑DLL4‑Notch3 pathway. Int J Cancer 146: 2218‑2228, 2020.
107. Wen Q, Chen Z, Chen Z, Chen J, Wang R, Huang C and Yuan W: EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin‑resistant gastric cancer cells. Oncotarget 8: 47998‑48011, 2017.
108. Gaianigo N, Melisi D and Carbone C: EMT and treatment resistance in pancreatic cancer. Biosci (Basel) 9: 122, 2017.
109. Peng F, Fan H, Li S, Peng C and Pan X: MicroRNAs in epithelial‑mesenchymal transition process of cancer: potential targets for chemotheraphy. Int J Mol Sci 22: 7526, 2021.
110. Li Z, Li M, Xia P and Lu Z: HOTTIP mediated therapy resistance in glioma cells involves regulation of EMT‑related miR‑10b. Front Immunol 12: 873561, 2021.
111. Loilome W, Joshi AD, ap Rhys CM, Piccirillo S, Vescovi AL, Gallia GL and Riggins GJ: Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling. J Neurooncol 94: 359‑366, 2009.
112. Suzuki M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20: 810‑817, 2011.
113. Brueher F, Ruddy D, Timiona D, Damen L, Engelmann J and Hata A: Abstract A142: Targeting FGFR to overcome EMT‑related resistance in EGFR‑mutated non‑small cell lung cancer. Mol Cancer Ther 17 (1 Suppl): 142, 2018.
114. Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B et al: SHP‑2‑upregulated ZEB1 is important for PDGF‑R driven glioma epithelial‑mesenchymal transition and invasion in mice and humans. Oncogene 35: 5641‑5652, 2016.
115. Brichkina A, Nguyen NT, Baskar R, Wei S, Gunaratne J, Robinson KC and Bulavin DV: Proline isomerisation as a novel regulatory mechanism for SMAPK activation and functions. Cell Death Differ 23: 1592‑1601, 2016.
116. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances matrix metalloproteinase‑2 secretion and invasion of glioma cells through Sputa growth factor receptor‑mediated e38/Akt and phosphatidylinositol 3‑kinase/Akt signaling pathways. Cancer Res 66: 851‑8519, 2006.
112. Trigg RM, Zhou Y, Wang BD, Hsu Y, Wang J, Zhang DD, Zhang L and Zhu L: Temozolomide and radiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol 116: 45-48, 2016.

113. Holder SL, Poon WS, Cheung KS, Lam KS and Lim HK: The targetable kinase PIM1 drives ALK inhibitor resistance in glioblastoma cells. Cancer Res 61: 5843-5849, 2001.

114. Bobustic GC, Assi KH, Marolda MC, Alway SS, Guo X, Luu D, Li M, Lin Y, Wang CY, Yan H, et al: Expression of PIM1 kinase as a target in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18: 10, 2019.

115. Zhang L and Zhu L: Temozolomide and irradiation combined treatment with anti-PD-L1 antibody and role of PI3K/AKT/mTOR for cancer therapy. J Hematol Oncol 12: 71, 2019.

116. Jiang Y, Wang J, Xing K, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 8: 383, 2009.

117. Kong T, Liu Q, Yu W, Zhu S, Cheng K, Xu H, Lv Y, Long X, Ma L, Huang J, Sun S and Wang K: Long noncoding RNA GAS5 regulates the proliferation, migration, and invasion of glioma cells by negatively regulating miR-18a-5p. J Cell Physiol 234: 757-768, 2020.

118. Li et al: lncRNAs REGULATE TMZ RESISTANCE IN GLIOMA.
138. Zhao X, Liu Y, Zheng J, Liu X, Chen J, Liu L, Wang P and Xue Y: GAS5 suppresses malignancy of human glioma stem cells via a miR-196a-5p/FOXO1 feedback loop. Biochim Biophys Acta Mol Cell Res 1864: 1605-1617, 2017.

139. Huo JF and Chen XB: Long noncoding RNA growth arrest-specific 5 facilitates glioma stem cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner. J Cell Biochem 120: 6127-6136, 2019.

140. Li G, Cai Y, Wang C, Huang M and Chen J: LncRNA GAS5 regulates the proliferation, migration, invasion and apoptosis of brain glioma cells through targeting GSTM3 expression. The effect of LncRNA GAS5 on glioma cells. J Neurooncol 143: 525-536, 2019.

141. Yan Y, Xu Z, Dai S, Qian L, Sun L and Gong Z: Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res 35: 23, 2016.

142. Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, Peng R and Cheng L: LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem 118: 1889-1899, 2017.

143. Jing H and Lee S: NF-kB in cellular senescence and cancer treatment. Mol Cells 37: 189-195, 2014.

144. Sánchez Y, Segura V, Marín-Béjar O, Athie A, Marchese FP, González J, Bujanda L, Guo S, Matheu A and Huarte M: Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun 5: 5812, 2014.

145. Torres-Bayona S, Aldaz P, Auzmendi-Iriarte J, Saenz-Antoñanzas A, Garcia I, Arrazola M, Gerovska D, Undabeitia J, Querejeta A, Egaña L, et al: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors. Sci Rep 8: 12746, 2018.

146. Ding H, Cui L and Wang C: Long noncoding RNA LIFR-AS1 suppresses proliferation, migration and invasion and promotes apoptosis through modulating miR-4262/NF-κB pathway in glioma. Mol Cells 37: 189-195, 2014.

147. Gao XY, Zhang J, Zheng MH, Zhang YF, Yue KY, Cao XL, Cao Y, Li XX, Han H, Jiang XF and Liang L: Temozolomide treatment induces HMGB1 to promote the formation of glioma stem cells via the TLR2/NEAT1/Wnt pathway in glioblastoma. Front Cell Dev Biol 9: 620883, 2021.

148. Wang C, Chen Y, Wang Y, Liu X, Liu Y, Li Y, Chen H, Fan C, Wu D and Yang J: Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and LncRNA NEAT1. J Exp Clin Cancer Res 38: 371, 2019.